Theranostics Horizons Spring Edition 2010 Newsletter
Commercial Availability of Enhanced CancerTYPE ID® assay and KRAS/BRAF
bioTheranostics Announces Commercial Agreement with Ferrer inCode
Medscape CME/CE
Molecular Classification of Cancers of Uncertain and Unknown Primary
CancerTYPE ID® provides molecular classification of uncertain or unknown cancer types.
Learn More >
Breast Cancer IndexSM predicts breast cancer recurrence risk based on proprietary molecular biomarkers, H/I and MGI.
Learn More >
Access Clinical Publications
Register for Clinical Updates
Request a Specimen Shipping Kit
View Patient Testimonial
Learn about CancerTYPE ID
Learn More About Metastatic Cancers